Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report

Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report

The relapse rate for children with juvenile myelomonocytic leukemia (JMML) status post hematopoietic stem cell transplantation (HSCT) approaches 50% within 5 years. Graft-versus-leukemia (GVL) is thought to play important role in the treatment of JMML. For this reason, careful management of immunosu...

Full description

Bibliographic Details
Main Authors: Shivani Y. Upadhyay MD, Satiro N. De Oliveira MD, Theodore B. Moore MD
Format: Article
Language:English
Published: SAGE Publishing 2017-09-01
Series:Journal of Investigative Medicine High Impact Case Reports
Online Access:https://doi.org/10.1177/2324709617728528

Similar Items

Similar Items